Sarah Cianférani Selected Research

Neoplasms (Cancer)

10/2021	High-Resolution IMS-MS to Assign Additional Disulfide Bridge Pairing in Complementarity-Determining Regions of an IgG4 Monoclonal Antibody.
5/2021	State-of-the-Art Native Mass Spectrometry and Ion Mobility Methods to Monitor Homogeneous Site-Specific Antibody-Drug Conjugates Synthesis.
1/2020	VHH characterization.Recombinant VHHs: Production, characterization and affinity.
1/2019	Multi-omics dataset to decipher the complexity of drug resistance in diffuse large B-cell lymphoma.
12/2017	Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
1/2016	TCTP contains a BH3-like domain, which instead of inhibiting, activates Bcl-xL.
1/2016	Cutting-edge mass spectrometry methods for the multi-level structural characterization of antibody-drug conjugates.
8/2015	Functional insights from high resolution structures of mouse protein arginine methyltransferase 6.
1/2014	Comparative expression study of the endo-G protein coupled receptor (GPCR) repertoire in human glioblastoma cancer stem-like cells, U87-MG cells and non malignant cells of neural origin unveils new potential therapeutic targets.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sarah Cianférani Research Topics

Disease

9	Neoplasms (Cancer) 10/2021 - 01/2014
4	Breast Neoplasms (Breast Cancer) 01/2022 - 08/2015
3	Bacillary Dysentery (Shigellosis) 11/2020 - 01/2017
2	Multiple Sclerosis 01/2022 - 01/2018
2	Inflammation (Inflammations) 01/2021 - 09/2020
1	Malaria 05/2021
1	Infections 06/2020
1	Urinary Bladder Neoplasms (Bladder Cancer) 01/2019
1	Friedreich Ataxia (Friedreich's Ataxia) 01/2019
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 01/2019
1	Phenylketonurias (Phenylketonuria) 01/2018
1	Hematologic Neoplasms (Hematological Malignancy) 01/2018
1	Glioblastoma (Glioblastoma Multiforme) 01/2014

Drug/Important Bio-Agent (IBA)

4	Pharmaceutical PreparationsIBA 05/2021 - 08/2015
3	EnzymesIBA 01/2022 - 01/2018
3	Monoclonal AntibodiesIBA 10/2021 - 01/2016
3	Immunoconjugates (Immunoconjugate)IBA 05/2021 - 01/2016
2	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2019
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 08/2015
2	queuine tRNA-ribosyltransferaseIBA 01/2018 - 01/2017
1	Antimalarials (Antimalarial Agents)IBA 05/2021
1	plasmodioneIBA 05/2021
1	SuspensionsIBA 01/2021
1	Silicon Dioxide (Silica)FDA LinkGeneric 09/2020
1	DNA (Deoxyribonucleic Acid)IBA 06/2020
1	ErbB Receptors (EGF Receptor)IBA 01/2020
1	AlbuminsIBA 01/2020
1	monomethyl auristatin EIBA 01/2020
1	HexokinaseIBA 01/2019
1	SulfurIBA 01/2019
1	FrataxinIBA 01/2019
1	Biological ProductsIBA 01/2019
1	IronIBA 01/2019
1	S100 Proteins (S 100 Protein)IBA 01/2019
1	Phenobarbital (Luminal)FDA Link 01/2019
1	Actin Depolymerizing Factors (Cofilins)IBA 01/2018
1	sapropterin (tetrahydrobiopterin)FDA Link 01/2018
1	Transfer RNA (tRNA)IBA 01/2018
1	Ado-Trastuzumab EmtansineIBA 12/2017
1	Translationally-Controlled 1 Tumor ProteinIBA 01/2016
1	human ERBB2 proteinIBA 08/2015
1	Maytansine (Maitansine)IBA 08/2015
1	Lysine (L-Lysine)FDA Link 08/2015
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2014

Therapy/Procedure

4	Therapeutics 01/2022 - 01/2014
2	Drug Therapy (Chemotherapy) 11/2020 - 01/2017
1	Radiotherapy 01/2014
1	Aftercare (After-Treatment) 01/2014